Cross Border

The target is one of France’s leading independent environmental platforms.

Qiagen develops molecular diagnostics, sample preparation technologies and life sciences research tools used in clinical testing, pharmaceutical research and academic laboratories.

The acquisition adds another specialist MGA with an established underwriting track record to AGI's platform.

The acquired portfolio comprises 12 acute-care hospitals across the U.K. that continue to be operated by Spire Healthcare.

The fund will invest in sector-agnostic, growth-oriented European mid-market businesses, typically making equity investments below approximately $286 million.